Interestingly, in an ongoing clinical trial for CRC patients combining the PD-1 inhibitor nivolumab with the CTLA-4 inhibitor ipilimumab, an improved efficiency was suggested in the combination therapy group [22]. The gene discussed is PDCD1; the disease is colorectal carcinoma.